Both C-reactive protein (CRP) and fit-microglobulin (fi2M) are established prognostic markers in MM. We tested the diagnostic value of these markers in 212 serum samples of patients with paraproteinemia registered prospectively in a population-based registry. 
0 DISTINGUISH multiple myeloma (MM) from other monoclonal gammopathies, several diagnostic classification systems have been developed' that make use of the presence of a paraprotein, osteolytic lesions, and plasmacytosis in the bone marrow, supplemented by other known tumor markers, as well as by symptoms and signs. The best known tumor marker in this disease is the paraprotein concentration.' However, paraproteins are seen in many different diseases, including other hematologic malignancies (B-cell non-Hodgkin's lymphoma [NHL] and mature B-cell leukemias), as paraneoplastic phenomenon in solid tumors, in autoimmune diseases, and in accompanying infection^."^ Often, no apparent cause is found (the so-called monoclonal gammopathy of undetermined significance [MGUS] ).' These entities must be distinguished from MM.
Neural cell adhesion molecule (NCAM; CD56) has been described as distinguishing between normal and malignant plasma cells in bone marrow.6-8 This glycoprotein, which can be both membrane-bound and soluble, is expressed on malignant plasma cells, as well as on natural killer cells, subsets of T lymphocytes, neuroectodermal cells, myeloid 1 with chronic lymphatic leukemia, and 1 with autoimmune disease had serum NCAM values between 20 and 30 UlmL. In a discriminant analysis in which serum NCAM, CRP, fi2M. paraprotein type and concentration, hemoglobin, leukocyte and thrombocyte counts, creatinine, corrected calcium, lactate dehydrogenase, and alkaline phosphatase were included, paraprotein type and concentration and serum NCAM turned out to be the best combination of parameters predicting whether a patient had MM, with 89% of cases being correctly classified. Even without bone marrow and x-ray examinations, serum NCAM, in combination with paraprotein type and concentration, can differentiate between MM and nonmyeloma patients. leukemia cells, trophoblast cells, and small cell lung carcinoma. It was recently discovered that serum NCAM could be used as a prognostic marker in Higher serum NCAM values were observed in patients with more advanced disease and shorter survival times. However, hardly any information on NCAM levels in paraproteinemias due to other causes exists.
The Comprehensive Cancer Center West (CCCW) initiated a population-based registry of all patients with a paraproteinemia newly diagnosed between 1991 and 1994 in the midwestern part of The Netherlands. Because this project also comprised an archive of serum samples at first diagnosis of patients included in the registry, we decided to test the diagnostic value of serum NCAM on a number of serum samples of patients with MM and well-defined monoclonal gammopathies of other causes. In addition, we analyzed two established prognostic markers, 02-microglobulin (02M) and C-reactive protein (CRP), which together form a prognostic staging system," and extracted data on other laboratory tests from the registry, to determine whether a combination of blood tests, without the help of bone marrow or x-ray examinations, could be sufficient to separate MM from other monoclonal gammopathies.
PATIENTS, MATERIALS, AND METHODS
Patients. Serum samples at first diagnosis were obtained in the course of a population-based registry performed in the CCCW region (1.7 million inhabitants), which included all patients newly diagnosed in 1991, 1992, and 1993 with a paraproteinemia andor MM. The study involved a registration of patient characteristics (age, sex, and performance status), results of x-ray and bone-marrow examinations, laboratory data (hemoglobin, leukocyte and thrombocyte counts, serum creatinine, lactate dehydrogenase [LDH], alkaline phosphatase, calcium, albumin, total protein, and type and concentration of the paraprotein in serum and urine), final classification in relation to the paraprotein, the presence of other diseases, therapy, a yearly follow-up, and the storage of 1 mL of serum at first diagnosis. The serum samples were stored at -80°C in one of the participating hospitals.
Paraproteins were detected by either agarose or celluloseacetate electrophoresis, depending on the hospital in which the patient was first seen (14 hospitals in the CCCW region, of which sera from 7 hospitals [9 locations] were used in this study). To be included in , myeloproliferative (n = 7; 6 myelodysplastic syndrome and 1 promyelocytic leukemia), and other (n = 4; 2 Hodgkin's disease, 1 cryoglobulinemia, and 1 hemolytic anemia without autoantibodies). The other 655 serum samples were not eligible for the following reasons: no definite diagnosis was made by the local physician or the diagnosis could not be confirmed; no clinical data were available as yet; or the serum had not been taken at first diagnosis or not enough serum was left for combined NCAM, p2M, and CRF' determinations.
The diagnosis MM was made when at least two of the following criteria were present'.": paraprotein in serum or urine, lytic bone lesion(s), or more than 10% plasma cells in bone marrow cytology. A paraprotein in serum (but not in urine), with more than 10% plasma cells, in the absence of symptoms, anemia, leucocytopenia, thrombocytopenia, hypercalcemia, renal failure due to myeloma, or lytic bone lesions was termed indolent MM.'.'' Any paraprotein without indications of MM or other hematologic or other malignancies or autoimmune disease with less than 10% plasma cells in bone marrow aspirate was termed MGUS.
Laboratory methods. Serum samples which had been stored at -80°C were used for serum NCAM, C m , and 82M determinations. Thawed samples were shipped on ice to Marburg University (Marburg, Germany), where serum NCAM determinations were performed. CRP and 82M determinations were performed immediately after thawing in the Westeinde Hospital (The Hague, The Netherlands).
For serum NCAM determinations, the eNCAM RIA-gnost immunoassay (Behringwerke AG, Marburg, Germany) was used. 82M was determined with a solid-phase two-side chemiluminescent enzyme immunometric assay (Immulite 82M; Diagnostics Products Corp, Los Angeles, CA), and a human CRP mammalian antibody was used for determination of CRP by rate nephelometry (Array Protein System, Beckman Instruments Inc, Galway, Ireland). Interassay coefficients of variation for serum NCAM were 2% to 8% (range, 8 to 113 U/mL); for p2M, 7% to 10% (range, 1.1 to 8.1 mg/ L); and for CRP, 58% (range, 10 to 90 m a ) . Normal values were less than 20 U/mL for serum NCAM, 1 to 3 mg/L for p2M, and less than 10 m g L for CRP. The serum NCAM, CRP, and p2M determinations were performed on blinded samples. Other laboratory results were extracted from the registry.
Statistics. Statistical methods to compare MM versus nonmyeloma included Mann-Whitney's test, Pearson's x ' test, and MantelHaenszel test for linear association. Subgroups of MM and nonmyeloma were compared using analysis of variance. Discriminant analysis was used to investigate stepwise whether a combination of laboratory tests was superior to differentiate between MM and nonmyeloma as compared with one single test. Analyses were performed using SPSS/PC+; data were entered in a database using SPSS Data Entry I1 (both SPSS Inc, Chicago, E).
RESULTS
Normal serum NCAM values (<20 U/mL) were present in 148 of 152 nonmyeloma cases; high values (220 U/mL) The results of several laboratory tests for myeloma and nonmyeloma patients are given in Table 3 . LDH was abnormal in 37 of 151 nonmyeloma patients and 7 of 60 MM patients ( P = .038; not performed in 1 patient), whereas alkaline phosphatase was abnormal in 38 of 128 nonmyeloma and l 1 of 55 MM patients ( P = NS; not performed in 29 patients). Of nonmyeloma cases, 41 were IgM, 104 were IgG, and 7 were IgA, whereas of MM patients, 42 had IgG, 13 had IgA, 1 had IgD, and 4 had light chain disease.
A discriminant analysis was performed to determine the combination of laboratory tests contributing mostly to the diagnosis MM or nonmyeloma. The following variables were entered: serum NCAM, CRP, P2M, paraprotein type and concentration, hemoglobin, leukocyte and thrombocyte counts, and creatinine. Paraprotein type was entered using two dummy variables that discriminated IgM, IgG/IgA, and IgDAight chain only. Ten cases with missing values could not be included in the analysis, leaving 202 patients. The concentration of paraprotein was the most important factor to predict diagnosis, followed by paraprotein type and serum NCAM. Extending the analysis to include corrected serum calcium, LDH, and alkaline phosphatase (the latter 2 being entered as dichotomous variables coding normal and abnormal values) did not alter the results. Because of missing values, only 161 of 212 cases could be used in that analysis. Entering the variables CRP and P2M separately or combined in the risk score described by Bataille et all0 did not contribute significantly to the model. When we ran the same analysis using only the three selected factors (paraprotein concentration, paraprotein type, and serum NCAM), 209 cases were ONG ET AL evaluable. All three factors made highly significant contributions ( P < .001) to the final model to discriminate between MM and nonmyeloma, with serum NCAM being chosen immediately after paraprotein concentration and before paraprotein type. Of 209 cases, 89% could be correctly classified as belonging to the MM or nonmyeloma group. Even when we excluded IgM paraproteins from the analysis (using 171 of 212 cases) the result stayed the same, with 88% of cases correctly classified when serum NCAM, paraprotein type (IgG/IgA v IgD/light chains), and paraprotein concentration were combined. The correlation between serum NCAM and paraprotein concentration was low (Y = .36).
Of 105 patients with a paraprotein concentration of less than 10 g/L and hemoglobin levels 26.2 mmol/L (10 g/ dL), 3 had serum NCAM levels 2 2 0 U/mL. Two patients diagnosed with CLL and autoimmune thrombocytopenia had only mildly elevated serum NCAM values (530 U/mL). The other patient had stage 111 MM and had a serum NCAM concentration of 70 U/mL.
DISCUSSION
In recent years, many potential prognostic markers for myeloma survival have been reported. Some of these are standard laboratory tests, such as thrombocyte count, LDH, and creatinine,I3"' and others are recently discovered prognostic markers, such as P2M, CRP,'" and serum NCAM.9 New markers to diagnose MM and differentiate this disease from other monoclonal gammopathies are seldom reported. Most diagnostic classification systems use paraprotein levels, the percentage of plasma cells in bone marrow aspirates, and the presence of lytic bone lesions to make a definite diagnosis of MM, often supplemented by symptoms and signs and standard laboratory tests.' Only Kyle and GreippI6 incorporate specialized diagnostic tests into their system, such as P2M and the plasma cell and peripheral blood B-cell labeling index. Unfortunately, most of these are not readily available to most physicians. We evaluated whether a combination of blood tests only, without the help of additional tests, could sufficiently differentiate between MM and nonmyeloma patients with monoclonal gammopathies.
In patients with a paraproteinemia, serum NCAM alone turned out to be an extremely useful diagnostic test if elevated. A disadvantage was that, even though all nonmyeloma cases had low (<20 U/mL) or only slightly elevated (530 U/mL) NCAM values, only half of MM patients had high values. This accounts for the high specificity and positive PV and low sensitivity and negative PV. Of all laboratory tests evaluated in this study, serum NCAM was the second best marker to differentiate between MM and nonmyelomaassociated monoclonal gammopathies, with paraprotein concentration being the best marker.
In patients with low paraprotein concentration and normal hemoglobin values, 3 turned out to have elevated serum NCAM levels, of whom 2 with nonmyeloma conditions had levels less than 30 U/mL. In 1 patient with stage 111 MM, serum NCAM was high (70 U/mL), indicating its diagnostic value even when there was no suspicion of MM.
Serum NCAM has also been studied in small cell lung carcinoma. Values were high in this disease and low in other lung malignancies, indicating that serum NCAM may be used specifically for diagnostic purpose^.'^ In our material, the only patient with small cell lung carcinoma had a low serum NCAM concentration of 4.2 U/mL. The prognostic value of serum NCAM reported by Kaiser et a19 was tested using two prognostic staging systems: the system developed by Dune and Salmon" and the one by Bataillel' using CRP and P2M. Serum NCAM levels increased significantly with increasing MM stage in both systems, thus confirming its prognostic value in MM. In our material, the risk score by Bataille could not be used to separate MM from nonmyeloma cases.
In a discriminant analysis, paraprotein type and concentration, together with serum NCAM, proved to be the most important combination of factors predicting the outcome MM or nonmyeloma. This was true even when IgM paraproteins (indicating a nonmyeloma condition) were excluded from the analysis. The low correlation coefficient between serum NCAM and paraprotein concentration ( r = .36) indicates that serum NCAM has diagnostic value in myeloma additional to paraprotein concentration.
It has been observed that several initially promising immunochemical markers in monoclonal gammopathies (interleukin-6 [IL-61, CRP, and P2M) subsequently were negatively influenced by the presence of other malignancies, decreasing the discriminative difference found between MGUS and MM." A recent study showed that serum IL-6 was not diagnostic." For this analysis, we carefully selected a very large series of patients with nonmyeloma-associated paraproteinemias and found low serum NCAM levels in all nonmyeloma categories, including hematologic and other malignancies.
Therefore, we conclude that serum NCAM is of great value as a diagnostic marker in MM. A high percentage of patients will be correctly classified with the help of only three laboratory tests for which a single serum sample is sufficient. Even without the results of supplementary tests such as bone marrow and x-ray examinations, the majority of cases with a paraproteinemia were correctly classified as having MM or a nonmyeloma-associated monoclonal gammopathy. 
